Our Origin Story
Co-founded by strategic thought leaders Greg Dombal who led Halloran and Geoff Meyerson who leads Locust Walk, Franklin brings an entrepreneurial mindset that allows clients to leverage our deep knowledge and proven execution experience. We help you efficiently navigate complex regulatory and development hurdles with confidence.
Ben Franklin is the namesake of the main road through UNC Chapel Hill, alma mater of CEO Greg Dombal, and founder of the University of Pennsylvania, alma mater of Co-founder Geoff Meyerson.
His innovation, entrepreneurial mindset, and creativity permeate our culture and inspire our team to develop the next generation of therapeutic breakthroughs.
Ben’s ability to draw from diverse disciplines enabled him to solve complex problems and create lasting impact, a philosophy we apply to drug development.
Our Differentiation
Integrated Approach to
Product Development
Our seamless integration of product strategy, tactical planning, and execution is deliberately engineered for regulatory and commercial success.
Capital & Time
Efficient Mindset
We focus on what’s best for your program with right-sized engagements and product roadmaps that rapidly and cost-efficiently deliver therapies to patients who need them.
We Are SelectivE
WITH WHOM WE WORK
We partner exclusively with companies developing impactful products that address meaningful unmet medical needs. Not everyone will meet our rigorous standards—and that’s by design.
Our Services
From early strategy to regulatory approval, we deliver comprehensive support across every critical function of drug development. Our experience leads to successful INDs; smart clinical strategies to rapidly create product value; Breakthrough, Fast Track and Orphan Designations that enable development ; and efficient clinical studies producing robust data to support approvable NDA / BLAs.
CLINICAL
PRODUCT STRATEGY
Indication Selection & Clinical Development Plans
Stage appropriate Target Product Profiles
Define clinical study concepts and Target Sets
CLINICAL
PRODUCT TACTICS
Create protocols, IB & other study documents
Clinical budget & cost planning
Due Diligence for transactions or filings
Clinical
execution
Clinical Study (CRO) oversight & management
Create DSUR, Annual Reports & routine filings
Update and maintain CT.gov, CTIS, etc
REGULATORY
PRODUCT STRATEGY
Analyze and assess regulatory landscape
Define product appropriate regulatory strategies
Structure approaches for expedited pathways
REGULATORY
PRODUCT TACTICS
Create IND/CTA/IDE/Special Designation Filings
Transaction due diligence
Conduct FDA & other Health Authority Meetings
regulatory
execution
US Agent/Ex-US Health Authority Correspondent
Manage & publish submissions in various systems
Document and maintain regulatory compliance
>$5B
R&D Dollars Overseen
>100
REgulatory meetings
>20
product approvals
50
countries with trials
>100
first in human trials
>200
regulatory designations
>75
INDs filed
>200
efficacy trials
Contact Us
contact information
420 Boylston Street, 6th Floor Boston, MA 02116
Greg Dombal,
Co-founder & CEO
Write us or contact us on LinkedIn
Error: Contact form not found.